Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Evercore ISI Group Initiates Coverage On Augmedix with In-Line Rating, Announces Price Target of $6

Author: Benzinga Newsdesk | December 15, 2023 10:12am
Evercore ISI Group analyst Elizabeth Anderson initiates coverage on Augmedix (NASDAQ:AUGX) with a In-Line rating and announces Price Target of $6.

Posted In: AUGX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist